The c-Src/LIST Positive Feedback Loop Sustains Tumor Progression and Chemoresistance

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Chemotherapy resistance and treatment failure are significant challenges in clinical cancer therapy.
• c-Src, a proto-oncogene, is a key target for anti-cancer drugs, but resistance remains an issue.
• Existing c-Src inhibitors face challenges due to acquired drug resistance.

Purpose of the Study:

• To investigate a potential positive feedback loop involving c-Src and a novel long non-coding RNA (lncRNA).
• To characterize the function of this lncRNA, renamed lncRNA-inducing c-Src tumor-promoting function (LIST), in cancer progression and chemoresistance.
• To explore the therapeutic potential of the LIST/c-Src axis.

Main Methods:

• Identification and characterization of a novel lncRNA (LIST).
• Investigation of the interaction between LIST and c-Src, including LIST's regulation of c-Src phosphorylation.
• Analysis of the positive feedback loop where c-Src regulates LIST transcription via the NF-κB pathway.
• In vitro and in vivo experiments in multiple cancer types to assess LIST's role in chemoresistance and tumor progression.
• Evolutionary analysis of the LIST/c-Src interaction.

Main Results:

• A positive feedback loop between LIST and c-Src was uncovered, with LIST acting as a c-Src agonist.
• LIST promotes tumor chemoresistance and progression in vitro and in vivo.
• c-Src positively regulates LIST transcription through the NF-κB signaling pathway.
• The LIST/c-Src interaction is linked to evolutionary variations in c-Src, suggesting a human-specific regulatory layer.

Conclusions:

• The newly identified LIST/c-Src axis provides a mechanism for enhanced c-Src activity, contributing to cancer chemoresistance and progression.
• This axis is evolutionarily significant and holds high relevance in cancer.
• The LIST/c-Src axis is a promising prognostic biomarker and a potential therapeutic target for overcoming cancer treatment failure.